Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: June 2014

Valproate

Related content

Powered by UNSILO

Suggested reading

Asconapé JJ, Penry JK, Dreifuss FE, Riela A, Mirza W. Valproate-associated pancreatitis. Epilepsia 1993; 34: 177–183.
Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56: 172–177.
Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996; 46: 465–469.
Glaucer TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC. For the Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. New England Journal of Medicine 2010; 362: 790–799.
Hernandez-Diaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, Holmes LB. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78: 1692–1699.
Limdi NA, Shimpi AV, Faught E, Gomez CR, Burneo JG. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005; 64: 353–355.
Marson AG, Williamson PR, Clough H, Hutton JL, Chadwick DW; Epilepsy Monotherapy Trial Group. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 2002; 43: 505–513.
Mattson RH, Cramer JA, Collins JF; Dept. of VA Epilepsy Cooperative Study No. 264 Group. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. New England Journal of Medicine 1992; 327: 765–771.
Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, Kalayjian LA, Kanner A, Liporace JD, Pennell PB, Privitera M, Loring DW. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. New England Journal of Medicine 2009; 360: 1597–1605.
Patsalos PN. Antiepileptic drug interactions: a clinical guide, 2nd edition. 2013, Springer, London, UK; 2013.
Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E. Antiepileptic drugs – Best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239–1276.
Ramsey RE, Wilder BJ, Murphy JV, Holmes GL, Uthman B. Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic-clonic seizures. Journal of Epilepsy 1992; 5: 55–60.
Shallcross R, Bromley RL, Irwin B, Bonnett LJ, Morrow J, Baker GA. Child development following in utero exposure. Levetiracetam vs sodium valproate. Neurology 2011; 76: 383–389.
Sommerville KS, Dutta S, Biton V, Zhang Y, Cloyd JC, Uthman B. Bioavailability of a divalproex extended-release formulation versus the conventional divalproex formulation in adult patients receiving enzyme-inducing antiepileptic drugs. Clinical Drug Investigation 2003; 23: 661–670.
Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004; 45: 1330–1337.
Villareal HJ, Wilder BJ, Willmore LJ, Bauman AW, Hammond EJ, Bruni J. Effect of valproic acid on spike and wave discharges in patients with absence seizures. Neurology 1978; 28: 886–891.
Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB. Antiepileptic drug pregnancy registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64: 961–965.